Activity Overview

This educational activity is an archive of the live conference held on Sunday, January 25, 2026.

Target Audience

This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in lung cancers and breast cancers. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

Learning Objectives

Assess clinical trial evidence for current and emerging systemic therapies for use in the management of early-stage and advanced/metastatic breast cancer
Develop individualized treatment plans for patients with early-stage and advanced/metastatic breast cancer by incorporating high-level clinical trial evidence with tumor- and patient-specific factors

Module 1: Minimal Residual Disease and Triple-Negative Breast Cancer

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.

Module 1: Minimal Residual Disease and Triple-Negative Breast Cancer

GET STARTED WITH THIS PROGRAM:

Related Content